AYAL Capital Advisors Ltd lifted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 14.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,000 shares of the medical research company’s stock after purchasing an additional 2,500 shares during the period. Bio-Rad Laboratories comprises about 2.1% of AYAL Capital Advisors Ltd’s portfolio, making the stock its 9th largest holding. AYAL Capital Advisors Ltd’s holdings in Bio-Rad Laboratories were worth $6,060,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of BIO. Capital Research Global Investors purchased a new position in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $117,303,000. Massachusetts Financial Services Co. MA increased its stake in shares of Bio-Rad Laboratories by 4,534.4% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 399,207 shares of the medical research company’s stock valued at $120,956,000 after purchasing an additional 390,593 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Bio-Rad Laboratories by 2,271.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 397,171 shares of the medical research company’s stock valued at $111,363,000 after purchasing an additional 380,422 shares in the last quarter. Boston Partners purchased a new position in shares of Bio-Rad Laboratories in the 4th quarter valued at about $75,037,000. Finally, Mangrove Partners IM LLC purchased a new position in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $35,568,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on BIO. Wells Fargo & Company cut their price target on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a research note on Friday, May 1st. Citigroup lowered Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their price target for the company from $375.00 to $300.00 in a research note on Tuesday, April 7th. Weiss Ratings lowered Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. Finally, Royal Bank Of Canada began coverage on Bio-Rad Laboratories in a research note on Friday, May 15th. They issued an “outperform” rating and a $320.00 price target for the company. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of “Hold” and a consensus target price of $303.33.
Bio-Rad Laboratories Trading Down 1.8%
BIO stock opened at $284.77 on Thursday. The company has a current ratio of 3.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.12. Bio-Rad Laboratories, Inc. has a 12-month low of $228.40 and a 12-month high of $343.12. The stock has a market cap of $7.62 billion, a price-to-earnings ratio of 46.91 and a beta of 1.08. The business’s 50-day moving average is $284.41 and its 200 day moving average is $290.07.
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.97 by ($0.08). Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The firm had revenue of $592.10 million during the quarter, compared to analyst estimates of $589.91 million. During the same quarter in the previous year, the firm posted $2.54 earnings per share. The company’s quarterly revenue was up 1.1% on a year-over-year basis. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.42 EPS for the current fiscal year.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.
Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.
Further Reading
- Five stocks we like better than Bio-Rad Laboratories
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
